International law firm Osborne Clarke has advised SCVC on the launch of its new $100 million investment fund focused on health and climate deep technology.
SCVC is an active lead investor in UK deep tech companies. It invests at the early-stage in pre-seed / seed rounds and can support through to series A investments. These include advanced technologies ranging from biotech to quantum tech, partnering with companies aligned with its mission of improving the health of people and the planet.
The new fund, targeting $100m in commitments, will invest at pre-seed and seed stage with initial cheque sizes of $500,000 up to $3 million. It will also provide follow-on funding of Series A tickets up to $7 million. Its first investment is VyperCore, a RISC-V startup developing modified processors.
SCVC was founded by Harry Destecroix who also co-founded biotech startup Ziylo while studying for his PhD at the University of Bristol. Destecroix is joined by SCVC co-founder Jon Craton, an angel investor and former co-founder of Zynstra, which was acquired by NCR Corporation.
Catherine Fletcher, principal at SCVC, commented: "Osborne Clarke was the perfect fit for us - efficient, pragmatic and effortlessly able to interpret our needs into reality. Helen Parsonage and her team were a pleasure to work with and I cannot recommend them highly enough."
Osborne Clarke is a leading European law firm for companies operating in the life science and healthcare sector. Its sector team has a strong track record of providing highly sophisticated advice to investors and life science and healthcare clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma, medical devices, medtech and digital health companies in the market.